BCAX250516P5000
- 0.00
- 0.000.00%
Bicara Therapeutics Newsroom
Bicara Therapeutics Says Updated Data From Ongoing Phase 1/1b Clinical Trial Of Ficerafusp Alfa In 1L R/M HNSCC To Be Highlighted In Oral Presentation At 2025 ASCO Annual Meeting
Wells Fargo Initiates Bicara Therapeutics(BCAX.US) With Sell Rating, Announces Target Price $8
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target
H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $44
Express News | HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $44
New Analyst Forecast: $BCAX Given $48.0 Price Target
TD Cowen Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $48
Bicara Therapeutics | 10-K: FY2024 Annual Report
Bicara Therapeutics Price Target Raised to $48 From $47 at Stifel
Bicara Therapeutics | 8-K: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Bicara Therapeutics: $490M in Cash and Cash Equivalents Expected to Fund Ops Into the 1H of 2029 >BCAX
Bicara Therapeutics 4Q Loss $21M >BCAX
Bicara Therapeutics 4Q Loss/Shr 39c >BCAX
Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
12 Health Care Stocks Moving In Tuesday's After-Market Session